Company Profile
NGeneBio develops in vitro diagnostics companion diagnostics products and bioinformatics software. It offers BRCAaccuTest and BRCAaccuTest PLUS are reagent kits for breast and ovarian cancer, and hereditary breast and ovarian cancer syndrome.
Its portfolio also includes HEMEaccuTest, a clinical NGS kit for hematological malignancies, such as acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic/myeloproliferative neoplasm, multiple myeloma, and lymphoma, SOLIDaccuTest, a genetic variants screening for solid tumors, HLAaccuTest, an in vitro diagnostic medical device for human leukocyte antigen typing, and OncoaccuPanel, a solid tumor oncology next generation sequencing test, as well as NGeneAnalySys, a software for analysis of the genetic testing data; and EasyHLAanalyzer, which offers the HLA typing identifing human leukocyte antigen for histocompatibility antigens using data from NGS.
Additionally, it offers MTBaccuPanel, a diagnostic panel to test mycobacterium tuberculosis, identification of nontuberculous mycobacteria species, and detection of mutations associated with drug resistance
NGenePlex nCoV qRT-PCR Kit, a reagent of real-time reverse transcription-polymerase chain reaction assay intended for the qualitatively detecting nucleic acid of SARS-CoV-2 from patients infected or suspected of COVID-19. Incorporated in 2015, the company is headquartered in Seoul, South Korea.